NSE › Healthcare

Dr. Reddy's Laboratories Limited (DRREDDY)

NSE · Healthcare · Drug Manufacturers - Specialty & Generic

₹1,175.00+3.07%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

₹8,070 cr

Revenue YoY

-5.6%

Net profit

₹444 cr

Profit YoY

-68.7%

EPS

₹5.33

EPS estimate

₹9.13

Net margin

5.5%

EPS came in at 5.33 against a street estimate of 9.13 — a miss of 41.6%.

Key statistics

Market cap

₹94,961 cr

P/E

28.7

Forward P/E

26.1

P/B

2.49

Book value

₹460.31

EPS (TTM)

₹39.73

Dividend yield

0.70%

52-week high

₹1,406.00

52-week low

₹1,101.00

50-day MA

₹1,183.29

200-day MA

₹1,250.70

Beta

0.24

Analyst view

with an average price target of ₹1,265.77.

Shareholding

Promoters

30.13%

Institutions

52.79%

Recent filings & reports

Document	Date
Investor presentation · Q1 FY27 DR. REDDY'S LABORATORIES Q1 FY27 RESULTS SUMMARY HEADLINE NUMBERS • Total Revenues: ₹8,071 Cr (6% YoY growth, 7% QoQ growth) • EBITDA: ₹1,009 Cr at	2026-07-22
Quarterly results · Q1 FY27 DR. REDDY'S LABORATORIES LIMITED – Q1 FY27 SUMMARY For Retail Investors \| July 22, 2026 --- HEADLINE NUMBERS • Consolidated Revenues: ₹80,705 milli	2026-07-22
Q1 FY27 earnings call	2026-07-15
Annual report FY2026 DR. REDDY'S LABORATORIES LIMITED – FY2026 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Revenue: ₹335,933 million ($3.6 billion USD) in FY2026, up	2026-06-30
Q4 FY26 earnings call	2026-05-18
Investor presentation · Q4 FY26 DR. REDDY'S LABORATORIES LTD – Q4 & FY26 RESULTS SUMMARY HEADLINE NUMBERS • Q4FY26 Reported Revenue: ₹7,516 Cr (12% YoY growth, 14% QoQ growth) • Q4	2026-05-12
Quarterly results · Q4 FY26 DR. REDDY'S LABORATORIES LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • Full Year FY26 Revenue: ₹335,933 million, up 3.2% YoY (Q4 revenue ₹75,162 mi	2026-05-12
Q3 FY26 earnings call DR. REDDY'S LABORATORIES LIMITED – Q3FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Consolidated revenues: ₹8,727 crores (US$971 million), up 4.4% YoY, do	2026-01-27

Readable in the app.

Corporate actions

Action	Detail	Date
Dividend	₹8 / share ex-date Jul 10, 2026	2026-07-10

Deals & corporate news

Announcement	Date
Acquires Progynova and Cyclo-Progynova brands for HRT segment Dr. Reddy's Laboratories has acquired the brands Progynova® and Cyclo-Progynova® in India, marking its entry into the Hormone Replacement Therapy (HRT) segment. These are established pharmac	2026-02-18

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Dr. Reddy's Laboratories Limited — free to start.

Google Play App Store

Other Healthcare companies

Sun Pharmaceutical Industries Limited Divi's Laboratories Limited Torrent Pharmaceuticals Limited Apollo Hospitals Enterprise Limited Lenskart Solutions Ltd Zydus Lifesciences Limited Cipla Limited Laurus Labs Limited Max Healthcare Institute Limited Aurobindo Pharma Limited Lupin Limited Mankind Pharma Ltd

Data updated 2026-09-18.